Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9475	Companies
185442	Keywords
117783	Articles
99298	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 08/01/2025 at 13:00, 4 months 3 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine

Revenue Moderna Q2 2025 FDA Approvals
BRIEF

published on 08/01/2025 at 12:05, 4 months 3 days ago

UK Court Confirms Validity of Moderna's EP'949 Patent

Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE

published on 08/01/2025 at 12:00, 4 months 3 days ago

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio

MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF

published on 07/30/2025 at 22:10, 4 months 5 days ago

Moderna Gains European Approval for New COVID-19 Vaccine

COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE

published on 07/30/2025 at 22:05, 4 months 5 days ago

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1

COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF

published on 07/28/2025 at 13:05, 4 months 7 days ago

Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025

MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 4 months 7 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 4 months 10 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 4 months 10 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 5 months 4 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 8 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 13 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 43 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 38 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 43 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 28 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 1 hour 13 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 28 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 2 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 13 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 58 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 43 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 58 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 59 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE